Skip to main content

Day: February 13, 2025

Freddie Mac Announces Fourth Quarter and Full-Year Financial Results

MCLEAN, Va., Feb. 13, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today reported its Fourth Quarter and Full-Year 2024 financial results and filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission. The company’s Form 10-K and earnings press release, along with the Fourth Quarter 2024 financial results supplement are available now on the Investor Relations page of the company’s website. The company will hold a call at 9 a.m. Eastern Time (ET) today, February 13, 2025, to share its results with the media. The call will be concurrently webcast, and the replay will be available on the company’s website for approximately 30 days. Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability, and affordability in the housing market throughout all economic...

Continue reading

Stryker to participate in Citi’s 2025 Unplugged Medtech and Life Sciences Access Day

Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) will participate in Citi’s 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York. Stryker’s management will represent the Company in a presentation scheduled for 12:15 p.m. Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at www.stryker.com.  The webcast will be archived on the Investor Relations page of this site. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around...

Continue reading

Foremost Clean Energy to Attend Prospectors & Developers Association of Canada (PDAC) 2025 Convention

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) — Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (“Foremost” or the “Company”), a rapidly growing North American American uranium and lithium exploration company is pleased to announce that it is participating for the first two days in the upcoming Prospectors & Developers Association of Canada (PDAC) 2024 Convention – the world’s premier mineral exploration & mining convention – taking place March 02-05, 2025 at the Metro Toronto Convention Centre (MTCC) in Toronto, Canada. PDAC 2025 is the world’s premier mineral exploration and mining convention and the leading event for people, companies and organizations connected to mineral exploration. The annual award winning PDAC Convention in Toronto, Canada brings together over 27,000 attendees from over 135+...

Continue reading

Rezolve Ai to Acquire GroupBy Strengthening Market Leadership in Commerce Site Search and Digital Engagement

Strategic acquisition expands Rezolve Ai’s capabilities in Commerce Site Search, unlocking synergies with enterprise clients and global infrastructure NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) — Rezolve Ai (NASDAQ: RZLV), a global leader in AI-driven commerce solutions, today announced that it has entered into a purchase agreement to acquire GroupBy Inc. (www.groupbyinc.com), a leader in enterprise-grade site search, product discovery, and merchandising solutions. The acquisition’s completion is subject to the fulfilment or waiver of standard closing conditions. This bold move will reinforce Rezolve Ai’s position as a leader in transforming digital commerce experiences. Powering the Future of Digital CommerceGroupBy has spent over 12 years optimizing product discovery for some of the world’s most recognized brands, including...

Continue reading

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Completion of SON-1010 (IL12–FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR) Continued progress with clinical trials evaluating SON-1010 in combination with Atezolizumab, for Platinum-Resistant Ovarian Cancer (PROC) and in combination with trabectedin in certain advanced soft-tissue sarcomas (STS) SON-1210 bifunctional Interleukins 12 and 15, on FHAB platform, in combination with chemotherapy for the treatment of advanced solid tumors and metastatic pancreatic cancer expected to initiate clinical trial with first patient dosed in H1 calendar year 2025 Company has initiated a licensing partnership in India for SON-080 in October 2024 and reorganizes...

Continue reading

Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025 Secured Private Placement Financing of $15 Million in Upfront Gross Proceeds with the Potential to Receive up to an Additional $15 Million in Potential Warrant Exercise Proceeds for an Aggregate of Up to Approximately $30 Million in Potential Total Gross Proceeds PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aneurysmal subarachnoid...

Continue reading

Arbitral tribunal appointed for the arbitration proceedings concerning the redemption of minority shares in Innofactor Plc

Innofactor Plc | Stock Exchange Release | February 13, 2025 at 14:50 EET Arbitral tribunal appointed for the arbitration proceedings concerning the redemption of minority shares in Innofactor Plc As previously announced, Onni Bidco Oy (“Onni Bidco”) has, by submitting an application to the Redemption Board of the Finland Chamber of Commerce dated December 2, 2024, commenced redemption proceedings in respect of Innofactor Plc’s (“Innofactor”) minority shares by initiating arbitration proceedings in accordance with Chapter 18, Section 3 of the Finnish Companies Act in order to obtain ownership of all the issued and outstanding shares in Innofactor. Onni Bidco served its application to appoint an arbitral tribunal and to initiate arbitration proceedings in accordance with Chapter 18, Section 5 of the Finnish Companies Act on January 7, 2025. Onni...

Continue reading

Form 8.3 – [ALLIANCE PHARMA PLC – 12 02 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ALLIANCE PHARMA PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 12 02 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 11 02 2025] – (CGWL) – CORRECTION

This disclosure supersedes the previous one which contained the wrong date in section 1(e) FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.